These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2740287)

  • 1. [Immunohistochemistry in malignant mesothelioma].
    Mezger J
    Pathologe; 1989 May; 10(3):197. PubMed ID: 2740287
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
    Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
    Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pleural carcinosis in renal cell cancer or pleural mesothelioma? A contribution to differential diagnosis].
    Reissig A; Kriegsmann J; Fleck M; Berghäuser K; Kosmehl H; Raabe G
    Z Arztl Fortbild (Jena); 1992 Nov; 86(21):1059-66. PubMed ID: 1462668
    [No Abstract]   [Full Text] [Related]  

  • 4. Pleural sarcomatoid malignant mesothelioma consisting of histiocytoid cells.
    Kawahara K; Nagano T; Matsui K; Kawai T; Iwasaki T
    Pathol Int; 2007 Apr; 57(4):229-31. PubMed ID: 17316420
    [No Abstract]   [Full Text] [Related]  

  • 5. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma.
    Kao SC; Griggs K; Lee K; Armstrong N; Clarke S; Vardy J; van Zandwijk N; Burn J; McCaughan BC; Henderson DW; Klebe S
    Pathology; 2011 Jun; 43(4):313-7. PubMed ID: 21532523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma.
    Suster S; Moran CA
    Adv Anat Pathol; 2006 Nov; 13(6):316-29. PubMed ID: 17075297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D2-40-positive solitary fibrous tumors of the pleura: diagnostic pitfall of biopsy specimen.
    Naito Y; Ishii G; Kawai O; Hasebe T; Nishiwaki Y; Nagai K; Ochiai A
    Pathol Int; 2007 Sep; 57(9):618-21. PubMed ID: 17685935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleural mesothelioma presenting initially as empyema.
    Smith R; Nguyen GK
    Diagn Cytopathol; 2003 Aug; 29(2):119-21. PubMed ID: 12889054
    [No Abstract]   [Full Text] [Related]  

  • 11. Is galectin-3 antibody a useful marker in the diagnosis of malignant pleural mesothelioma?
    Mlika M; Ayadi-Kaddour A; Ksantini M; Bouraoui S; Mzabi S; El Mezni F
    J Immunoassay Immunochem; 2013; 34(2):111-25. PubMed ID: 23537297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
    Takeshima Y; Amatya VJ; Kushitani K; Kaneko M; Inai K
    Histopathology; 2009 May; 54(6):667-76. PubMed ID: 19438742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In search of a positive immunohistochemical marker for mesothelioma: an update.
    Ordóñez NG
    Adv Anat Pathol; 1998 Jan; 5(1):53-60. PubMed ID: 9868512
    [No Abstract]   [Full Text] [Related]  

  • 14. Validation of tissue microarray technology in malignant pleural mesothelioma.
    Kao SC; Lee K; Armstrong NJ; Clarke S; Vardy J; van Zandwijk N; Reid G; Burn J; McCaughan BC; Henderson DW; Klebe S
    Pathology; 2011 Feb; 43(2):128-32. PubMed ID: 21233673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
    Deniz H; Kibar Y; Güldür ME; Bakir K
    Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesothelioma as a risk indicator of asbestos exposure: the role of the pathologist.
    Zampi G; Comin CE; Dini S
    Med Lav; 1995; 86(5):389-92. PubMed ID: 8684289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
    Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
    Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology of malignant mesothelioma.
    Van Marck E
    Lung Cancer; 2004 Aug; 45 Suppl 1():S35-6. PubMed ID: 15261431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid hormone-related protein antigen localization distinguishes between mesothelioma and adenocarcinoma of the lung.
    Clark SP; Chou ST; Martin TJ; Danks JA
    J Pathol; 1995 Jun; 176(2):161-5. PubMed ID: 7636626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant mesothelioma of the pleura--diagnostic difficulties].
    Drozdowska A; Damps-Konstańska I; Kobierska-Gulida G; Madrzak J; Kuziemski K; Pieńkowska J; Ucińska R; Słomiński JM
    Pol Merkur Lekarski; 2004 Oct; 17(100):380-1. PubMed ID: 15690708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.